Inactive Instrument

Propanc Health Group Corp Stock price Other OTC

Equities

US74345C1027

Pharmaceuticals

End-of-day quote Other OTC
- USD 0.00% Intraday chart for Propanc Health Group Corp
Sales 2022 - Sales 2023 - Capitalization 559K
Net income 2022 -2M Net income 2023 -2M EV / Sales 2022 -
Net Debt 2022 1.09M Net Debt 2023 536K EV / Sales 2023 -
P/E ratio 2022
-0.07 x
P/E ratio 2023
-0.08 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 97.69%
More Fundamentals * Assessed data
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding CI
More news
Managers TitleAgeSince
Chief Executive Officer 50 07-10-14
Founder 77 07-10-14
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 50 07-10-14
Founder 77 07-10-14
Director/Board Member 74 20-12-22
More insiders
Propanc Biopharma, Inc. is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development of cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development.
More about the company
  1. Stock
  2. Equities
  3. Stock Propanc Biopharma, Inc.
  4. Stock Propanc Health Group Corp - Other OTC